Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma

PHASE3CompletedINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

October 31, 1995

Study Completion Date

December 31, 2001

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

recombinant interferon alfa

Trial Locations (14)

NW3 2QG

Royal Free Hospital, Hampstead, London

LS9 7TF

St. James's Hospital, Leeds

LE1 5WW

University Hospitals of Leicester, Leicester

SE1 7EH

Guy's, King's and St. Thomas' Hospitals Trust, London

SW3 6JJ

Royal Marsden NHS Trust, London

M20 4BX

Christie Hospital N.H.S. Trust, Manchester

L63 4JY

Clatterbridge Centre for Oncology NHS Trust, Merseyside

S1O 2SJ

Weston Park Hospital, Sheffield

AB25 2ZN

Aberdeen Royal Infirmary, Aberdeen

B29 6JD

Selly Oak Hospital, Birmingham

BH7 7DW

Royal Bournemouth Hospital, Bournemouth

PE30 4ET

Queen Elizabeth Hospital, Kings Lynn

SP2 8BJ

Salisbury District Hospital, Salisbury

SS0 0RY

Southend Hospital, Southend-on-Sea

All Listed Sponsors
lead

Institute of Cancer Research, United Kingdom

OTHER